and our platform. synthetic you progress, XXXX Good for Andrew. second joining milestones. on exciting time and financial to happy us. the This biotic and Synlogic share for quarter an the results update of today upcoming the is thank I'm for recent everyone, Thanks, morning,
most opinion announced In remainder new need the drug of our for second a an read PKU. three for advanced for the XXXX, quarter, we expect reflects the different Medicines on include For in PKU recognized Phase readouts from the clinical XXXX confirmation. from SYNB orphan Agency of Phase PKU. of EMA PKU, treatment designation European for received the step data we EMA's important opinion program, that we treatments candidate III and II is This program programs. These our the out and program for the in three positive data or
clinic promise within of built of on on synthetic the year biotherapeutics XXXX, SYNB this as SYNB biology, as based of just and SYNB XXXX, regulatory recognizing synergies XXXX, was chassis. Synthetic biotics. platform for entered package well a using the of the named transferable a preclinical of biotics traditional for synthetic XXXX done [indiscernible] as as also designed to to X our XXXX HCU, consume for than to the in potential share healthy program from potential a is XXXX study treatment recently less a recognize entire SYNBXXXX SYNB finally clinic expect we treatment Phase findings third concept timing and proof For recently the volunteer the candidate the XXXX, toxicology for being raised for homocystinuria FDA as SYNB SYNB as initiated findings SYNB We years, the two reflecting data. hyperoxaluria, of or technical enter advantages and
are especially Patients joint the or Synlogic to available range remain uric levels gout. to intolerant inflammatory often Moving and who those newest SYNBXXXX the of of of I'm motion pain well-known therapies. to the is refractory cause pipeline gout intense addition debilitating arthritis excited due limited and pipeline, beyond excessive the clinical to form for acid. underserved, a
was it partnership General our our Secretary. excited appointed St. advance And to share and been a Counsel that pleasure earlier second with Synlogic's to synthetic biotic through are developed Ginkgo Corporate SYNBXXXX, Amant finally, We Brendan Bioworks. has
readiness last activities for concept first on II and This PKU amino builds analysis call, start patients shared half the our the in data generation discussed SYNB at metabolize in reduction and activity while the presumed are head-to-head of the As XXXX on bridge X fall, III of and establishing of underway in XXXX. program Phase candidates. confirmed the aren’t greater trial patients readout, demonstrating PKU PKU with Phe, study we proof SYNB SYNBXXXX Phase III interim is concept with acid that strong it In levels. our for able of a last Phase the such safety potency the at now high we've to becomes Phase study. progressed, proof then, neurotoxic next even parallel XXXX, Since plasma
the However, the in XXXX that from be experience after this confirmed PKU assessing shared will study to II year. Phase be SYNB patient later
to Looking opportunity an ahead II to drug the this confirm use to we Phase remind the have endpoint data, activity. of we audience
the we that to they're assess biotic programs, our specific as end points multiple for For if look are synthetic intended. to working all of
the treatment PKU, we trial. For a at Phe the synthetic this primary GI symphony and designed Phe as DX test or more provide the To in is of in II labeled Phe This measure baseline tract. and a Phase metabolize endpoint precise part the is biotic again, our in meal effect for then to controlled study. after way,
assessing in our byproducts, produced metabolic be levels, the is fee on can which biotic HA Phe. impact effectively urine, synthetic and plasma also plasma We two if strain fasting as only are well in consuming as of TCA
to that, to the as well on Molly forward also from the to bit an differentiation our pass With but PKU, further in sharing HCU over program. on some monotherapy, call positioning a more and We color of this a perspective provide to look evaluation significance data Molly? as I'll our adjunct as as also [indiscernible].
